EVALUATION OF THE EFFICACY OF ATYPICAL ANTIPSYCHOTIC DRUGS AND PSYCHOTHERAPY IN PATIENTS WITH PARANOID SCHIZOPHRENIA BASED ON THE DURATION OF REMISSION.

Duration of remission (DR) is the equivalent of the risk of re-hospitalization, which is considered as evidence of unsuccessful completion of the prescribed treatment. The evidence of DR informativeness as a criterion for effectiveness of prescriptions is distribution of DR values among patients with re-hospitalization during the observation period. The aim of the study is to analyse the duration of remission as a criterion for the effectiveness of prescribing atypical antipsychotic drugs and psychotherapy for patients with paranoid schizophrenia. 4 groups of patients were formed: the study group No. 1 includes patients who received atypical antipsychotic drugs; the study group No. 2 includes patients who received atypical antipsychotic drugs and psychotherapeutic cortrection (PC); the control group No. 1 includes patients receiving typical antipsychotic drugs; the control group No. 2 includes patients who received typical antipsychotic drugs and PC. The total number of examined patients was 164 people, the average age was 29.25±13.5 years, the number of patients with a diagnosis of paranoid schizophrenia was 118, with a diagnosis of acute polymorphic psychotic disorder with symptoms of schizophrenia - 46. The average duration of the disease was 2.7±2.1 years. The statistical tobit model made it possible to objectify the results of the effectiveness of the combination of antipsychotic drugs, psychotherapy, and DR by the studied patients. We used the tobit model to test the power of hypotheses, i.e., the possibility of this model to determine the existing differences in the effectiveness of the compared treatment methods (Rosenbaum and Rubin, 1983; Wooldridge, J.M., 2012). The effectiveness of the treatment was evaluated by indicators of duration of the remission period by the patients and the risk of re-hospitalization due to disease relapse. We observed a clear dynamic of some patients to re-hospitalization during the observation period with the highest hospitalization rates in the first 100 days. Evidence of the tests powers was a clear prevalence of cases of re-hospitalization by the patients taking typical antipsychotic drugs (44 cases) compared with those among patients receiving atypical ones (12). There was a clear predominance of cases of prolonged remission by the patients who took atypical antipsychotic drugs (70) compared with those who received typical ones (38) among 108 of censored ones. It was determined that patients who took typical and atypical antipsychotic drugs entered remission with the same period, but its quality was different. It was found that the indices of DR by prescription of atypical antipsychotic drugs and PC were significantly higher compared with those of typical antipsychotic drugs - the integral difference in DR per patient was 140 days. The risk of re-hospitalization due to prescription of atypical antipsychotic drugs decreases on average by 87.8% compared with prescription of the typical ones, that is, prescription of atypical antipsychotic drugs significantly increases DR compared with prescription of typical antipsychotic drugs.